HOME > LATEST
LATEST
-
BUSINESS Genmab Targets 2027 US Debut for 2 Cancer Drugs, CEO Eyes Blockbuster Potential
April 23, 2026
-
BUSINESS Bayer Eyes 2026 Launch for Sevabertinib under “3-Plus-3” Strategy in Japan
April 23, 2026
-
REGULATORY JPMA Pushes for “Freeze” on On-Patent Drug Price Cuts at LDP Meeting
April 23, 2026
-
ORGANIZATION APAC Disbands Drug Discovery WG as Asia Capabilities Rise
April 23, 2026
-
ORGANIZATION Flight Cuts, Fuel Costs Tied to Iran Crisis Threaten API Imports: Trader
April 23, 2026
-
REGULATORY MHLW to Exclude High School-Age and Younger from OTC-Like Drug Charge: Official
April 23, 2026
-
REGULATORY Japan, Singapore to Share GMP Inspection Results under Cooperation Pact
April 23, 2026
-
BUSINESS iPark, Taiwan’s ITRI Ink MOU to Boost Biotech Collaboration
April 23, 2026
-
BUSINESS AbbVie, BioLabs Partner to Support Japan Biotech Startups
April 23, 2026
-
BUSINESS Lenvima-Keytruda Triplets Fail in First-Line RCC Trial
April 22, 2026
-
BUSINESS Another Global PIII Shuttered for Arcus-Partnered TIGIT Combo: Taiho
April 22, 2026
-
REGULATORY MHLW Orders Label Revisions for Remicade, Enbrel, Bavencio, and More Drugs
April 22, 2026
-
REGULATORY Extra Charges Likely for OTC-Like Drugs to Treat Seasonal Conditions: Minister
April 22, 2026
-
BUSINESS Imdelltra Likely to Gain Ground in 2nd-Line SCLC after Label Update: Oncologist
April 22, 2026
-
BUSINESS Jazz, Nippon Zoki Ink Deal to Bring Cannabis-Derived Epilepsy Drug to Japan
April 22, 2026
-
BUSINESS Padcev-Keytruda Gets FDA Priority Review for Cisplatin-Eligible Perioperative MIBC
April 22, 2026
-
BUSINESS Pfizer’s Tukysa Makes Japan Debut for HER2-Positive Breast Cancer
April 22, 2026
-
BUSINESS Novartis Japan Chief Urges Pro-Innovation Policies to Sustain Investments
April 21, 2026
-
ORGANIZATION JPMA to Set Up Task Force on US MFN Policy, First Meeting Seen This Month
April 21, 2026
-
REGULATORY Japan Panel to Review Boehringer’s IPF Drug, Moderna COVID Shot on April 27
April 21, 2026
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
